National Cancer Institute (nci)

This study tested a new treatment that takes a patient's own immune cells, modifies them in a lab to recognize and attack cancer cells with a specific marker (KK-LC-1), and gives them back. It was for adults with advanced stomach, breast, cervical, lung, or other epithelial cance…

This study tested a drug called SGI-110 (guadecitabine) in people aged 12 and older with rare cancers like wild-type GIST, pheochromocytoma, paraganglioma, or HLRCC-related kidney cancer that had not responded to other treatments. The goal was to see if the drug could shrink tumo…

This study tested a drug called BMS-986253 for people with myelodysplastic syndromes (MDS), a group of bone marrow cancers. The goal was to see if the drug was safe and could help control the disease. Only 2 adults enrolled before the study was stopped early, so no conclusions ab…

This early-phase study aimed to find the best dose and test the safety of combining dasatinib (a targeted cancer drug) with icosapent ethyl (an omega-3 fatty acid) in people with metastatic triple-negative inflammatory breast cancer, a rare and aggressive form. Only one participa…

This study tested two oral drugs, eltanexor and Inqovi, in adults with high-risk myelodysplastic syndromes (MDS) that did not improve with standard treatment. The goal was to find the best dose and see if the combination could control the disease. Only 3 people enrolled before th…